Neurodegenerative diseases: pathogenic mechanisms

2022 Activity indicators

4 public competitive projects
2 private competitive projects
4 competitive HR contract.
2 publications.
IF: 36.42
Publications in D1: 1 (50 %).
Publications in Q1: 2 (100 %).
Project evaluators: 2 PIs.
Members of Editorial Committees: 1 PI
1 European patent. Number EP2733205 on neural stem cell differentiation methods through CB1 modulation.

Sánchez de la Torre A, Aguado T, Huerga-Gomez A, Guzmán M, Monory K, Lutz B, Matute C, Mato S, Galve-Roperh I, Palazuelos J. CB1 cannabinoid receptors deficiency in oligodendrocyte precursor cells disrupts oligodendrogenesis and myelination in mice. Cell Death & Dis. 2022; 13:185. PMID: 35798697.
Manterola A, Chara JC, Aguado T, Palazuelos J, Matute C, Mato S. Cannabinoid CB1 receptor expression in oligodendrocyte progenitors of the hippocampus revealed by the NG2-EYFP-knockin mouse. Front. Neuroanat. 2022; 16:1030060. PMID: 36387996.
Galve-Roperh I, de Salas-Quiroga A, Simón S, Guzmán M. Prenatal THC exposure interferes with the neurodevelopmental role of endocannabinoid signaling. Book "Cannabis and the Developing Brain". Chapter 13. 2022; 259-282. https://doi.org/10.1016/B978-0-12-823490-7.00013-7.
Project "The cannabinoid CB1 receptor as a possible molecular nexus in non-syndromic intellectual disability". PID2021-125118OB-I00, MICIN - Proyectos de Generación de Conocimiento (2022). PI. Manuel Guzmán.
Project "Transcriptomic and functional regulation of cortical development by endocannabinoid signaling. Implication in neurodevelopmental diseases". PI21-00938, ISCIII/AES - Health Research Projects (2022). PI: Ismael Galve.

	Articles	Accum. IF	Mean IF	Articles QI or Q2	% in Q1 or Q2	Articles D1	% in D1
2018	5	21,32	4,26	4	80	2	40
2019	5	28,08	5,62	5	100	1	20
2020	10	128,66	12.87	10	100	7	70
2021	6	36,42	6,07	5	83	2	33
2022	2	13,23	6,61	2	100	1	50
	29	227,71	7,09	26	93	13	46